Method of producing recombinant high molecular weight vWF in cell culture

Patent metadata

Field	Value
Publication number	US-9834591-B2
Application number	US-201615201125-A
Country	US
Kind code	B2
Filing date	Jul 1, 2016
Priority date	Jul 8, 2010
Publication date	Dec 5, 2017
Grant date	Dec 5, 2017

Abstract

Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH 4 + ) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.

First claim

What is claimed is:

1. A cell culture supernatant comprising a recombinant Von Willebrand Factor (rVWF), wherein the cell culture supernatant is prepared by a method comprising the steps of:
(a) providing a basal cell culture media;
(b) supplementing the basal cell culture media with copper to provide a final copper concentration of at least 2.4 μg/L;
(c) providing one or more cells comprising a nucleic acid encoding a rVWF protein;
(d) culturing the one or more cells in the copper supplemented cell culture media such that rVWF is expressed and excreted from the cells into a culture supernatant and the NH 4+ content of the cell culture supernatant is maintained at a concentration below 4 mM or below 10 mM; and
(e) recovering at least a portion of the culture supernatant, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 30 mU/μg rVWF.

2. The cell culture supernatant of claim 1 , wherein the cell culture supernatant further comprises recombinant Factor VIII (rFVIII).

3. The cell culture supernatant of claim 2 , wherein the ratio of rVWF to rFVIII is at least 10:1.

4. The cell culture supernatant of claim 2 , wherein the cell culture supernatant is formulated for pharmaceutical administration.

5. The cell culture supernatant of claim 4 , wherein the cell culture supernatant is formulated for intravenous administration.

6. The cell culture supernatant of claim 1 , further comprising the step of supplementing the basal cell culture media with a hydrolysate prior to culturing the one or more cells.

7. The cell culture supernatant of claim 6 , wherein the hydrolysate is a plant hydrolysate.

8. The cell culture supernatant of claim 7 , wherein the hydrolysate is a soy hydrolysate.

9. The cell culture supernatant of claim 1 , wherein the basal cell culture media is an animal protein free culture media.

10. The cell culture supernatant of claim 1 , wherein the basal cell culture media is a protein free culture media.

11. The cell culture supernatant of claim 1 , wherein the basal cell culture media is a chemically defined culture media.

12. The cell culture supernatant of claim 1 , wherein the final copper centration of the copper supplemented basal cell culture media is at least 4 μg/L copper.

13. The cell culture supernatant of claim 1 , wherein the final copper concentration of the copper supplemented basal cell culture media is between 2.4 μg/L to 20 μg/L copper.

14. The cell culture supernatant of claim 1 , wherein the copper supplementing the basal cell culture media is provided as copper salt, copper chelate, or a combination thereof.

15. The cell culture supernatant of claim 14 , wherein the copper salt is selected from the group consisting of copper sulfate, copper acetate, copper carbonate, copper chloride, copper hydroxide, copper nitrate, and copper oxide.

16. The cell culture supernatant of claim 1 , wherein the one or more cells are mammalian cells.

17. The cell culture supernatant of claim 16 , wherein the mammalian cells are CHO cells.

18. The cell culture supernatant of claim 1 , wherein culturing the one or more cells comprises batch cultivation of the cells.

19. The cell culture supernatant of claim 1 , wherein culturing the one or more cells comprises continuous cultivation of the cells.

20. The cell culture supernatant of claim 19 , wherein the continuous cultivation of cells is performed in chemostatic mode.

21. The cell culture supernatant of claim 20 , wherein the continuous cultivation of cell is performed in perfusion mode.

22. The cell culture supernatant of claim 1 , wherein the one or more cell is cultured in at least 100 L of the supplemented basal cell culture media.

23. The cell culture supernatant of claim 1 , where the cell density is maintained at less than 2.5×10 6 cells per mL during the step of culturing the one or more cells.

24. The cell culture supernatant of claim 23 , where the cell density is maintained at less than 2.0×10 6 cells per mL during the step of culturing the one or more cells.

25. The cell culture supernatant of claim 23 , where the cell density is maintained at less than 1.5×10 6 cells per mL during the step of culturing the one or more cells.

26. The cell culture supernatant of claim 1 , wherein the step of recovering at least a portion of the cell culture supernatant comprises filtration or centrifugation to remove cells from the portion of culture supernatant.

27. The cell culture supernatant of claim 1 , wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 40 mU/μg rVWF.

28. The cell culture supernatant of claim 27 , wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 50 mU/μg rVWF.

29. The cell culture supernatant of claim 27 , wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 60 mU/μg rVWF.

30. The cell culture supernatant of claim 27 , wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 70 mU/μg rVWF.

31. The cell culture supernatant of claim 27 , wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 80 mU/μg rVWF.

32. The cell culture supernatant of claim 1 , wherein at least 10% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

33. The cell culture supernatant of claim 1 , wherein at least 20% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

34. The cell culture supernatant of claim 1 , wherein at least 30% of the rVWF in the supernatant is present in a high molecular weight VWF multimer of more than 10 dimers.

35. The cell culture supernatant of claim 1 , wherein the supernatant contains high molecular weight VWF multimers of 14 to 22 dimers.

36. The cell culture supernatant of claim 1 , wherein the one or more cells in step (c) further comprise a nucleic acid encoding recombinant Factor VIII (rFVIII) and the rFVIII is co-expressed with the rVWF protein.

37. The cell culture supernatant of claim 36 , further comprising a step of purifying rVWF away from at least 50% of the rFVIII present in the recovered supernatant.

38. The cell culture supernatant of claim 37 , wherein the ratio of rVWF to rFVIII after the purification step is at least 10:1.

39. The cell culture supernatant of claim 1 , wherein the method further comprises enriching for the rVWF protein within the cell culture supernatant.

Assignees

• Baxalta Inc
• Baxalta GmbH

Inventors

• Grillberger Leopold
• Reiter Manfred
• Mundt Wolfgang

Classifications

• C12Y304/24087

  ADAMTS13 endopeptidase (3.4.24.87) · CPC title

• C12P21/00

  Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title

• C12N2511/00

  Cells for large scale production · CPC title

• C12N2501/998

  Proteins not provided for elsewhere · CPC title

• C12N2500/24

  Iron; Fe chelators; Transferrin · CPC title